ZYMEWORKS INC. Forum: Community User: Karmate1

Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers https://www.businesswire.com/news/home/20211026005273/en/Zymeworks-Announces-Webcast-to-Present-HERIZON-GEA-01-Pivotal-Trial-Design-and-Zanidatamab-Commercial-Strategy-in-Gastrointestinal-Cancers ... Event: HERIZON-GEA-01 Conference Call and Webcast Date: Tuesday, November 9th Time: 4:15 p.m. ET ...

Ich hätte kein Problem damit, wenn er recht behält 🙃😉: Wells Fargo: These 3 Stocks Are Poised to Surge by at Least 40% https://finance.yahoo.com/news/wells-fargo-3-stocks-poised-151628025.html

👀

Zymeworks gets dosing underway in early-stage zanidatamab breast cancer study https://seekingalpha.com/news/3748990-zymeworks-gets-dosing-underway-in-early-stage-zanidatamab-breast-cancer-study • Zymeworks (NYSE:ZYME) and ALX Oncology Holdings (NASDAQ:ALXO) announce the first patient has been dosed in the early-stage trial of zanidatamab in certain patients with breast cancer. • The trial is designed to evaluate the safety and efficacy of zanidatamab in combination with evorpacept in patients with advanced HER2-positive breast cancer, HER2-low breast cancer and additional non-breast HER2-expressing solid tumors. • Zanidatamab is designed to have multiple mechanisms of action, including immune clearance of HER2‑expressing tumor cells by macrophages through antibody-dependent cellular phagocytosis (ADCP). • Zymeworks had posted data indicating that zanidatamab showed promising response rate and durability in esophageal cancer, last month.

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors https://www.businesswire.com/news/home/20211005005450/en/Zymeworks-and-ALX-Oncology-Announce-First-Patient-Dosed-in-Phase-1b2-Clinical-Trial-of-Zanidatamab-and-Evorpacept-ALX148-in-Patients-with-Advanced-HER2-Expressing-Breast-Cancer-and-Other-Solid-Tumors

Zymeworks Inc Files For Mixed Shelf Size Not Disclosed Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) https://www.marketscreener.com/quote/stock/ZYMEWORKS-INC-34658200/news/ZYMEWORKS-INC-Entry-into-a-Material-Definitive-Agreement-Financial-Statements-and-Exhibits-form-36575183/

Gefunden hatte ich aktuell nichts dazu. Rechnen muss man hier aber wahrscheinlich mit allem (positiv, wie negativ).

Lässt sich der Abfall des Kurses erklären?

Wird aktuell ziemlich runter gezogen. Aber-10? Sehe aktuell in NY -6%. Aber was nicht ist 🤪... Na mal schauen.

-10% ?

Mid-stage data show disruptive potential of zanidatamab https://www.thepharmaletter.com/article/mid-stage-data-show-disruptive-potential-of-zanidatamab?__cf_chl_jschl_tk__=pmd_L39C4FWH5Itn_PGnV.t_y.MEjG50q8itsYPVy6Rz13Y-1631891236-0-gqNtZGzNAmWjcnBszQi9 ... Chief executive Ali Tehrani said: “Our long-standing vision for zanidatamab has been for it to become a best-in-class HER2‑targeted therapeutic that could address the needs of a broad spectrum of patients with HER2‑expressing cancers.” He added: “As we embark on our second pivotal trial and prepare for commercialization, these data represent a landmark moment for zanidatamab and for Zymeworks.”

Recent Zymeworks zanidatamab data could "intensify" sale talk - Dealreporter https://seekingalpha.com/news/3740870-recent-zymeworks-zanidatamab-data-could-intensify-sale-talk-dealreporter Clinical data presented this week from Zymeworks (ZYME -0.5%) on zanidatamab for esophageal cancer "'could intensify potential sale talks," according to Dealreporter. Data on zanidatamab in combination with other chemotherapy agents presented at the European Society for Medical Oncology 2021 Congress showed a confirmed objective response rate of 75% overall and 93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP). Zymeworks has a market cap of $1.53B. In its Q2 2021 earnings, the company missed on both EPS and revenue.

Zymeworks squares up with Herceptin after HER2 bispecific aces mid-stage test in esophageal cancer https://endpts.com/zymeworks-squares-up-with-herceptin-after-her2-bispecific-aces-mid-stage-test-in-esophageal-cancer/

https://www.businesswire.com/news/home/20210912005060/en/Zymeworks-Announces-Abstract-for-Zanidatamab-in-First-line-HER2-Expressing-Gastroesophageal-Cancers-GEA-at-the-European-Society-for-Medical-Oncology-ESMO-Annual-Congress

Zymeworks Reports 2021 Second Quarter Financial Results https://www.businesswire.com/news/home/20210804006023/en/Zymeworks-Reports-2021-Second-Quarter-Financial-Results